QNRX

Quoin Pharmaceuticals' New Video Release: Quoin Pharmaceuticals has released the fourth episode of its "NETHERTON NOW" video series featuring Mandy Aldwin-Easton, a patient advocate for Netherton Syndrome, who shares her challenging experiences with the disease and emphasizes the need for hope and better treatment options.

Advancements in Treatment: The company is advancing its product candidate QRX003 through pivotal clinical trials aimed at treating Netherton Syndrome, highlighting the urgency to address the significant unmet medical needs within this underserved community.

Q2 2025 Financial Performance: Quoin Pharmaceuticals reported a GAAP EPS of $(6.28), surpassing estimates, with R&D expenses tripling to $2.05 million due to increased clinical activities, while cash reserves decreased to approximately $7.8 million.

Clinical and Regulatory Progress: The company achieved significant milestones for its lead asset QRX003, including positive trial results for Netherton Syndrome and regulatory approvals from the FDA and EMA, although it continues to operate without revenue.

Quoin Pharmaceuticals' New Video Release: Quoin Pharmaceuticals has released a new episode in its NETHERTON NOW video series featuring Professor Jemima Mellerio, who discusses the severe challenges of Netherton Syndrome, a genetic skin condition affecting infants and young children, emphasizing the need for better treatment options.

FDA Designation for QRX003: The FDA has granted Rare Pediatric Disease Designation to Quoin's lead product candidate, QRX003, aimed at treating Netherton Syndrome, highlighting the urgency for effective therapies for this serious pediatric disease.